Clinical Trial Update: An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy [Phase 2]

View source ↗

Summary

Phase 2 open-label trial of mazindol extended release (NLS-2) in narcolepsy with and without cataplexy completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Narcolepsy
• Narcolepsy Without Cataplexy
• Narcolepsy with Cataplexy

Drugs mentioned

• NLS-2 (Mazindol Extended Release) (mazindol extended release)

Snippet

Sponsor: NLS Pharmaceutics | Conditions: Narcolepsy With Cataplexy, Narcolepsy | Phase 2 | Status: COMPLETED